Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats. by 신전수 et al.
Yang et al. Respiratory Research 2014, 15:148
http://respiratory-research.com/content/15/1/148RESEARCH Open AccessGlycyrrhizin, inhibitor of high mobility group box-1,
attenuates monocrotaline-induced pulmonary
hypertension and vascular remodeling in rats
Pil-Sung Yang1, Dae-Hoon Kim1, Yong Joon Lee2, Sang-Eun Lee1, Won Jun Kang3, Hyuk-Jae Chang1,4* and
Jeon-Soo Shin2,4Abstract
Background: High mobility group box-1 (HMGB1), a proinflammatory cytokine, plays a pivotal role in tissue remodeling
and angiogenesis, both of which are crucial for the pathogenesis of pulmonary arterial hypertension. In this study, we
explored the relationship between HMGB1 and pulmonary hypertension and whether glycyrrhizin, an inhibitor of
HMGB1, attenuates disease progression in an animal model of pulmonary hypertension induced by monocrotaline
sodium (MCT).
Methods: After inducing pulmonary hypertension through a single subcutaneous injection of MCT (60 mg/kg) to
Sprague–Dawley rats, we administered daily intraperitoneal injections of either glycyrrhizin (GLY, 50 mg/kg), an inhibitor
of HMGB1, or saline (control) for either 4 or 6 weeks.
Results: Expression levels of HMGB1 in serum increased from the second week after MCT injection and remained
elevated throughout the experiment periods. Lung tissue levels of HMGB1 assessed by immunohistochemical staining at
4 weeks after MCT injection also increased. Chronic inhibition of HMGB1 by GLY treatment reduced the MCT-induced
increase in right ventricular (RV) systolic pressure, RV hypertrophy (ratio of RV to [left ventricle + septum]), and pulmonary
inflammation. MCT-induced muscularization of the pulmonary artery was also attenuated in the GLY-treated group. As
assessed 6 weeks after MCT injection, the GLY-treated group exhibited increased survival (90% [18 of 20]) when
compared with the control group (60% [12 of 20]; p =0.0027).
Conclusions: Glycyrrhizin, an inhibitor of HMGB1, attenuates pulmonary hypertension progression and pulmonary
vascular remodeling in the MCT-induced pulmonary hypertension rat model. Further studies are needed to
confirm the potential of HMGB1 as a novel therapeutic target for pulmonary hypertension.
Keywords: High mobility group box-1 (HMGB1), Pulmonary hypertension, Pulmonary vascular remodeling,
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Pulmonary arterial hypertension is a fatal disease charac-
terized by elevated pulmonary vascular resistance that
ultimately leads to right ventricular (RV) failure and death
[1]. Despite current therapeutic approaches for improving
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unless otherwise stated.they still have a limited effect on vascular remodeling and
do not confer a mortality benefit [2,3].
Like many other vasculopathies, pulmonary hyperten-
sion is characterized by severe angioproliferative vascular
remodeling. Inflammation is considered to play a central
role in disease progression in various types of pulmonary
hypertension [4-8]. Serum levels of multiple chemokines
and cytokines related to inflammatory processes are ele-
vated, and inflammatory cells such as macrophages, T and
B lymphocytes, and dendritic cells infiltrate vascular
lesions in pulmonary hypertension patients.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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fied as a nuclear non-histone DNA-binding protein, which
stabilizes nucleosome structure and regulates transcription
[9,10]. HMGB1 localizes to the nucleus under normal con-
ditions and is released to the extracellular milieu in
response to inflammatory stimuli. HMGB1 mediates vari-
ous systemic inflammations such as sepsis, arthritis, and
autoimmune diseases [11-13] by binding to cellular recep-
tors such as the receptor for advanced glycation end prod-
ucts (RAGE), toll-like receptor (TLR)-2 and TLR-4 [14,15].
HMGB1 is also involved in tissue remodeling and angio-
genic activities; it promotes migration and proliferation of
smooth muscle cells [16,17] and mediates the activation
and migration of endothelial cells [18,19].
Considering the pathophysiology of pulmonary hyper-
tension and the role of HMGB1 in inflammatory processes
and tissue remodeling, there is reasonable probability that
HMGB1 may be associated with the pathogenesis of pul-
monary hypertension, an angioproliferative vasculopathy.
A recent study also reported that serum HMGB1 levels
were higher in idiopathic pulmonary hypertension patients
than in healthy controls, and HMGB1 may contribute to
the pathogenesis of experimental pulmonary hypertension
induced by chronic hypoxia [20].
In this study, we explored the relationship between
HMGB1 and pulmonary hypertension, investigating
whether HMGB1 inhibition by glycyrrhizin attenuates
disease progression of pulmonary hypertension and in turn
translates into mortality benefit, by using a well-established




This animal study protocol was approved by Institutional
Animal Care and Use Committee of Yonsei University
Health System, in accordance with the Guide for the Care
and Use of Laboratory Animals (National Research Council,
USA). We performed animal experiments twice, for 4-week
and 6-week periods, to evaluate both the established
stage and the end stage of pulmonary hypertension. Male
Sprague–Dawley rats (body weight 240–260 g) were ran-
domly divided into 3 groups in each experiment: Group 1,
initially given a single subcutaneous injection of normal sa-
line and no treatment (control group; n = 5 [4 weeks] and
10 [6 weeks]); Group 2, initially given a single subcutaneous
injection of MCT (0.5 ml, 60 mg/kg; c2401; Sigma-Aldrich)
and once daily intraperitoneal treatment of normal saline
(MCT group; n = 10 [4 weeks] and 20 [6 weeks]); and
Group 3, initially given a single subcutaneous injection of
MCT (0.5 ml, 60 mg/kg) and once daily intraperitoneal
treatment of glycyrrhizin (GLY) (50 mg/kg; 50531; Sigma-
Aldrich) (MCT +GLY group; n = 10 [4 weeks] and 20
[6 weeks]). After the above animal experiments, anadditional experiment was performed to verify the effects
of GLY alone without MCT on the pulmonary vascular
system. An initial single subcutaneous injection of normal
saline and once daily intraperitoneal treatment of GLY
(50 mg/kg) for 4 weeks was performed in male Sprague–
Dawley rats (GLY group; n = 6). The MCT was dissolved
in 1.0 N HCl, and the pH was adjusted to 7.4 with 0.5 N
NaOH. A dose of 50 mg/kg GLY was selected on the basis
of previous animal studies using GLY [21,22]. A timeline
of the animal experiments is illustrated in Figure 1.
Measurement of the level of HMGB1 in the lung tissue
and serum
Rat lung tissues were harvested 28 days after MCT
injection and immunohistochemical staining with a mouse
monoclonal anti-human HMGB1 antibody (ab18256;
Abcam) was performed. Serum was separated 0, 1, 3, 7,
14, 21, and 28 days after MCT injection from the tail
vein and stored in a -70o C deep freezer. The HMGB1 level
in the serum was analyzed by an ELISA kit (Shino-Test,
Japan) in accordance with the manufacturer’s instructions.
Measurement of RV pressure and hypertrophy, tissue
preparation
Hemodynamic measurement and organ harvesting were
performed at the end of the animal experiments, 4 weeks
or 6 weeks post MCT or normal saline injection. To
monitor hemodynamics, rats were anesthetized with
Zoletil (50 mg/kg; Virbac) and Rompun (5 mg/kg;
Bayer). Mechanical ventilation was applied with a tidal
volume of 10 mL/kg and a respiratory rate of 60
breaths/min. The chest was opened, and a right heart
catheter (PE-50 tube) was directly inserted into the RV
through the cardiac apex for measurement of right
ventricular systolic pressure (RVSP) with force transduc-
ers (Edwards Lifesciences Corporation). After measuring
RV pressure, the lung vascular bed was flushed by inject-
ing cold phosphate-buffered saline (PBS). The left lung
was fixed in 10% neutral buffered formalin for histologic
examination. The heart was separated from the thoracic
cavity and the RV was dissected from the left ventricle
(LV) and the septum (S). Each part of the heart was
weighed to determine the degree of RV hypertrophy
from the ratio of RV to [LV + S].
Histologic examination of the lungs
Histologic examination of the lungs was performed as
described previously [23]. Elastica-eosin staining was per-
formed according to common histological procedures to
identify the medial area between the internal elastic lam-
ina and external elastic lamina. Sections were examined
using a virtual microscopy system (dotSlide; Olympus,
Japan). Forty muscular arteries with external diameters
from 50 to 100 μm were analyzed for each animal. The
Figure 1 Scheme of animal experimental timeline. Pulmonary hypertension was induced by a single subcutaneous injection of MCT (60 mg/kg).
The GLY (50 mg/k) was intraperitoneally treated once daily immediately after MCT injection for 4 weeks or 6 weeks in the MCT + GLY group, while
normal saline was injected in the MCT group. Hemodynamic changes, RV hypertrophy, histological changes of lung, micro-PET, and survival rate were
measured at the end of the animal experiment.
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as 2 × media thickness/external diameter × 100. Medial
wall thickness was measured along the shortest curva-
ture of the vessel. Double immunohistochemical stain-
ing with mouse monoclonal anti-human alpha smooth
muscle actin (α-SMA) antibody (diluted 1:400; M0851;
DAKO) and rabbit polyclonal anti-human von Willeb-
rand factor (vWF) antibody (diluted 1:1000; A0082;
DAKO) was performed to assess the degree of muscu-
larization of the pulmonary arteries. Sections were
counterstained with hematoxylin and examined using
the virtual microscopy system. Sixty small pulmonary
vessels with external diameters from 10 to 50 μm were
counted at × 400 magnification for each rat. Counted
vessels were categorized as fully muscularized, partially
muscularized, or nonmuscularized by observers blinded
to treatment. Nonmuscularized arterioles were detected
by endothelial anti-vWF staining.
Measurement of the degree of pulmonary inflammation
by micro-positron emission tomography (PET)
A micro-PET scanner (Concorde Microsystems Inc, USA)
was used to detect and quantify lung inflammation.
Micro-PET scanning was performed with an injection of
2–3 MBq of 18 F-FDG in the tail vein after 28 days of
MCT injection (normal control group, n = 5; MCT group,
n = 5; MCT +GLY group, n = 5). Subjects were fasted forat least 6 hours before scanning. Circular regions of inter-
est were placed on the lung field, and the standardized up-
take value (SUV), which represents pulmonary FDG
uptake per unit volume, was calculated as [mean regions
of interest count (cps/pixel) × body weight (kg)]/[injected
dose (mCi) × calibration factor (cps/mCi)] using free soft-
ware, Amide’s a Medical Image Data Examiner.Culture of human pulmonary artery endothelial cells
(HPAEC) and endothelin 1 (ET-1) release assay
HPAEC (CC-2530; Lonza) were cultured in commercial
HPAEC medium (EGM-2, Lonza) supplemented with
penicillin (100 U/ml)–streptomycin (100 μg/ml), 10%
fetal bovine serum (FBS) at 37oC in a humidified 5%
CO2 incubator. All experiments were performed on
endothelial cells within the fifth passage. HPAEC was
seeded in 96-well plates (1×104 cells/well) for 24 hours,
and recombinant HMGB1 (R&D systems) was treated to
HPAEC in various concentrations (10, 20, 30, and 40 ng/
ml) for 24 hours. To inhibit the ET-1 release induced
by HMGB1, anti-HMGB1 antibody (ab18256; Abcam)
(0.2 μg/ml, 1 μg/ml) and anti-RAGE antibody (ab3611;
Abcam) (0.2 μg/ml, 1 μg/ml) were co-treated with
recombinant HMGB1 of 40 ng/ml. The culture super-
natant was harvested, and ET-1 release was measured
using a commercial human ET-1 ELISA kit (#900-020A;
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turer’s instructions.
Culture of human pulmonary artery smooth muscle cells
(HPASMC) and proliferation assay
HPASMCs were supplied from Lonza and cultured accord-
ing to the supplier’s instructions. All experiments were exe-
cuted on smooth muscle cells within the fifth passage. A
proliferation assay was performed as described previously
[24]. HPASMCs were seeded in 6-well plates (1×105 cells/
well) with commercial HPASMC basal medium (SmBM;
Lonza) supplemented with 5% FBS and growth factors.
The medium was replaced with serum-free SmBM 24 hours
after seeding. After 16 hours, we divided HPASMCs into
three groups. The first group was cultured with serum-free
medium alone. The second group was cultured with the
medium in the presence of 10% FBS. The third group was
cultured with the medium in the presence of HMGB1
(30 ng/ml). HPASMCs were incubated for 3 days and
counted at 1, 2, and 3 days. Trypan blue dye was used to
evaluate the viability of cells. Experiments were performed
two times in duplicate.
Statistical analysis
All data are given as means ± SEM. Differences between
the groups were assessed by analysis of variance and the
Bonferroni post hoc test. The survival rate was presented
as a Kaplan-Meier curve and compared by a log-rank
test. A p-value less than 0.05 was considered significant.
Results
HMGB1 levels increased in the MCT-induced pulmonary
hypertension rat model
To examine the relationship between HMGB1 and pul-
monary hypertension, we investigated the patterns and
levels of HMGB1 expression in lung tissues at 28 days
and measured serum levels of HMGB1 at 0, 1, 3, 7, 14,
21, and 28 days after inducing pulmonary hypertension
by MCT.
In lung tissues of the normal control rats, no inflamma-
tory cells were observed as shown by hematoxylin and
eosin staining (Figure 2A), and immunohistochemical
staining with anti-HMGB1 antibody showed that HMGB1
was mainly localized to the nucleus (Figure 2B-C). How-
ever, in lung tissues of the MCT-induced pulmonary
hypertension rats, many inflammatory cells were recruited
to the lungs (Figure 2D), and HMGB1 was localized to
both the nucleus and the cytoplasm (Figure 2E-F). Cyto-
plasmic translocation of cellular HMGB1 from the nu-
cleus to the cytoplasm suggests subsequent release of
HMGB1 into the extracellular milieu [25]. Cytoplasmic
translocation of HMGB1 was also observed in vascular
endothelial cells, smooth muscle cells, and recruited
inflammatory cells in the MCT-induced pulmonaryhypertension rats (Figure 3A-D). The proportions of
cytoplasmic-HMGB1-positive cells in lung tissue was
higher in the MCT-induced pulmonary hypertension
rats (65.4% ±6.5%) than in the normal control rats
(6.7% ±0.8%; p <0.001) (Figure 2G). Compared with the
baseline, serum levels of HMGB1 measured by ELISA
assays significantly increased 2–4 weeks after MCT
injection (baseline: 2.2 ± 0.2 ng/ml; 2 weeks: 4.6 ±
0.3 ng/ml; 3 weeks: 3.9 ± 0.2 ng/ml; 4 weeks: 5.1 ±
0.4 ng/ml; all p <0.001), while control rats did not
exhibit a significant increase of HMGB1 serum levels
(Figure 2H).
Inhibition of HMGB1 by GLY treatment reduced MCT-induced
increases of RV systolic pressure, RV hypertrophy, medial wall
thickness, and muscularization of pulmonary arteries
Based on our results linking HMGB1 and pulmonary
hypertension, we tested the effects of GLY, an HMGB1
inhibitor, on hemodynamic features and vascular remodeling
in MCT-induced pulmonary hypertension rats.
RVSP significantly increased in the MCT injection
group at both 4 weeks (58.54 ± 7.67 mmHg) and 6 weeks
(75.75 ± 3.21 mmHg) after MCT injection, compared with
the control group (28.11 ± 0.85 mmHg; p = 0.002). Treat-
ment of GLY reduced the MCT-induced increase of RVSP
from 58.54 ± 7.67 mmHg to 39.17 ± 3.22 mmHg (4 weeks
post-MCT injection; p = 0.045) and from 75.75 ±
3.20 mmHg to 56.75 ± 2.28 mmHg (6 weeks post-MCT
injection; p = 0.002). In GLY given alone without MCT,
there was no significant difference in RVSP when com-
pared with the control group (p = 0.307). Therefore, the
inhibition of HMGB1 by GLY treatment can attenuate
hemodynamic changes in MCT-induced pulmonary hyper-
tension rats (Figure 4A).
The ratio of RV to LV weight plus the S weight (RV/
(LV + S)) expresses the degree of RV hypertrophy. Com-
pared to the control group (0.2572 ± 0.0079), the RV/
(LV + S) value increased significantly in the MCT
groups at both 4 weeks (0.4898 ± 0.0404) and 6 weeks
(0.6397 ± 0.0097) after the MCT injection (p <0.001).
GLY treatment reduced the value of RV/(LV + S) from
0.4898 ± 0.0404 to 0.4403 ± 0.0437 at 4 weeks after MCT
injection (p = 0.418) and from 0.6397 ± 0.0097 to 0.5596 ±
0.0204 at 6 weeks after MCT injection (p = 0.002) in the
MCT +GLY group. In GLY given alone without MCT,
there was no significant difference in the RV/(LV + S)
value when compared with the control group (p = 0.656).
These data demonstrate that RV hypertrophy developed
in the MCT group and that this change could be attenu-
ated through the inhibition of HMGB1 by GLY treatment
(Figure 4B).
The medial wall thickness (expressed as a percentage of
total wall thickness) was analyzed in pulmonary arteries





Figure 2 Increased tissue and serum levels of HMGB1 in pulmonary hypertension rats induced by MCT. A–C: Lung sections of normal
control rats. D–F: Lung sections of MCT-induced pulmonary hypertension rats at day 28 after MCT injection. A, D: Hematoxylin and eosin staining.
B, C, E, F: Immunohistochemical staining with anti-HMGB1 antibody (brown). (A) No inflammatory cell was observed in the lungs of normal
control rats. (B, C) HMGB1 was mainly localized to the nucleus (black arrow). (D) A large number of inflammatory cells (white arrow) were
recruited to the lungs of MCT-induced pulmonary hypertension rats. (E, F) HMGB1 translocated to the extranuclear area (triangle). (G) The proportion
of cytoplasmic HMGB1 positive cells in lung tissue of MCT-induced pulmonary hypertension rats was greater than in that of normal control rats
(*p <0.001). (H) Serum levels of HMGB1 in MCT-injected rats increased significantly 2 weeks after the MCT injection and remained elevated (*p <0.001
when compared to initial serum level of HMGB1). Data are presented as means ± SEM (n =10).
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between the lamina elastica interna and externa. In the
MCT group, the medial wall thickness significantly in-
creased compared with the control group (control group:
14.98% ±0.56%; MCT group, 4 weeks: 26.51% ±0.68%;
MCT group, 6 weeks: 29.59% ±0.83%; p <0.001). Upon
treatment with GLY, the MCT-induced increase in medial
wall thickness was attenuated from 26.51% ±0.68% to
19.93% ±0.62% at 4 weeks after MCT injection (p <0.001)and from 29.59% ±0.83% to 22.91% ±0.67% at 6 weeks
after MCT injection (p <0.001) in the MCT +GLY group.
GLY treated alone without MCT did not cause a signifi-
cant difference in medial wall thickness when compared
with the control group (p = 0.501) (Figure 5A-B).
The degree of muscularization of pulmonary arteries
with external diameters between 10 to 50 μm was also
analyzed. To this end, we performed double immuno-
histochemical staining of lung tissue with anti-α-SMA
A B
Figure 4 Inhibition of HMGB1 by GLY treatment attenuated the MCT-induced increase of RV systolic pressure and RV hypertrophy.
(A) MCT-injected rats exhibited increased RVSP when compared with control rats (*p = 0.002). GLY treatment reduced the MCT-induced increase of
RVSP (†p = 0.045 when compared to the MCT group treated for 4 weeks; ‡p = 0.002 when compared to the MCT group treated for 6 weeks). GLY
treated alone without MCT yielded no significant difference in RVSP when compared with that of control rats (p = 0.307). (B) RV hypertrophy (RV/(LV + S))
increased significantly in the MCT group when compared with the control group (**p <0.001). GLY treatment reduced the MCT-induced increase of RV
hypertrophy, although only rats given a 6-week GLY treatment course exhibited a statistically significant difference (††p = 0.418 when compared with the
MCT group treated for 4 weeks; ‡‡p = 0.002 when compared with the MCT group treated for 6 weeks). GLY treated alone without MCT yielded no
significant difference in RV hypertrophy when compared with that of controls (p =0.656). Data are presented as means ± SEM.
A B
C D
Figure 3 Expression pattern of HMGB1 in the pulmonary vascular lesion. Immunohistochemical staining with anti-HMGB1 antibody (brown
color) and counterstaining with hematoxylin was performed on lung tissues of normal control rats and MCT-induced pulmonary hypertension rats
at day 28 after MCT injection. A, C: Sections of large arteries. B, D: Sections of small vessels of lung tissue. (A, B) In normal control rats, HMGB1
was present only in the nuclei of smooth muscle cells (black arrow) and endothelial cells (black triangle). (C, D) However, in MCT-induced
pulmonary hypertension rats, HMGB1 was present in both the nuclei and cytoplasm of smooth muscle cells (white arrow) and endothelial cells
(white triangle). There were many inflammatory cells around the vessels with cytoplasmic HMGB1 translocation in MCT-induced pulmonary
hypertension rats (white asterisk).








Figure 5 MCT-induced increases in both medial wall thickness and muscularization of pulmonary arteries were attenuated through the
HMGB1 inhibition by GLY treatment. (A, B) Elastica-eosin staining showing that the medial area between the lamina elastica interna and
externa (deep violet) increased in the MCT group when compared with the normal control group (*p <0.001). Treatment with GLY attenuated
the medial change induced by MCT injection (†p <0.001). GLY treated alone without MCT yielded no significant difference in medial wall thickness
when compared with that of control rats (p = 0.501). (C, D) The degree of muscularization of pulmonary arteries was observed via immunostaining of
α-SMA (brown) and vWF (purple). In the MCT group, the proportion of muscularized pulmonary arteries increased when compared with the control
group (■p <0.001). GLY treatment attenuated this MCT-induced muscularization of pulmonary arteries (♦p <0.001). GLY treated alone without MCT
yielded no significant difference in pulmonary artery muscularization when compared with that of control rats (p = 0.262). Data are presented
as means ± SEM.
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former identified the smooth muscle layer of the vessel,
whereas staining with the latter distinguished the endo-
thelial layer of the vessel. In the MCT group, the
amount of nonmuscularized pulmonary arteries de-
creased; however, the amount of fully muscularized pul-
monary arteries increased compared to the control
group (p <0.001). In contrast, upon GLY treatment,
muscularization of pulmonary arteries in the MCT
group significantly decreased at both 4 and 6 weeks in
the MCT + GLY group (p <0.001). GLY treated alone
without MCT displayed no significant difference inpulmonary artery muscularization when compared with
the control group (p = 0.262) (Figure 5C-D).
Inhibition of HMGB1 by GLY treatment improved the
survival rate and reduced inflammation of the lung in the
MCT-induced pulmonary hypertension rat model
Next, we observed whether inhibition of HMGB1 influ-
ences survival. For this purpose, MCT-injected rats were
treated with GLY, and their survival rate was compared
to that of rats in the MCT group. In the MCT group, the
survival rate decreased to 60% (12 of 20 animals) at
42 days post-MCT injection. In contrast, when GLY was
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improved to 90% (18 of 20 animals) in the MCT +GLY
group (Kaplan-Meier analysis; p = 0.0027) (Figure 6A). In
a complementary approach, we also measured the degree
of pulmonary inflammation by micro-PET imaging at
28 days post-MCT injection. In the micro-PET technique,
radiotracer uptake is proportional to the degree of inflam-
mation present. Increased levels of radiotracer uptake
were observed in lung tissue from animals in the MCT
group when compared with the control group, and this
increased uptake was attenuated with GLY treatment
(Figure 6B). To quantify radiotracer uptake, we calculated
the SUV, which expresses the 18 F-FDG uptake per unit
volume in the lung field. SUVs increased in the MCT
group compared with the control group. Upon treatment
with GLY, however, SUVs decreased significantly, from
0.4724 ± 0.098 to 0.2931 ± 0.016 (p = 0.018) in the
MCT + GLY group (Figure 6C).
HMGB1 induced ET-1 release from HPAECs and proliferation
of HPASMCs
To determine whether HMGB1 plays a role in endothelial
hyperactivity in pulmonary hypertension, we quantified
ET-1 release from cultured HPAECs after stimulation with
HMGB1. Release of ET-1 was higher in the HMGB1-
treated (40 ng/ml) group (109.7%; 381.92 ± 7.1 pg/ml)
than in the non-treated control group (348.23 ± 12.2 pg/
ml; p <0.001) (Figure 7A). Furthermore, HMGB1 increased
the release of ET-1 from HPAECs in a dose-dependent
manner (range, 10–40 ng/ml). Moreover, the addition
of antibodies against HMGB1 (1 μg/ml) significantlyA
Nor
B
Figure 6 Effect of GLY treatment on survival rate and pulmonary infla
(A) GLY was administered for 42 days, and rat survival was compared with th
MCT group; in contrast, the survival rate was 90% in the MCT + GLY group (*p
by micro-PET at 28 days post-MCT injection. The SUV of the lung field increas
GLY treatment reduced the SUV of the lung field when compared with that o
as means ± SEM.attenuated HMGB1-induced ET-1 release (at 40 ng/ml
HMGB1) from 384.16 ± 1.3 pg/ml to 359.63 ± 5.1 pg/
ml (p = 0.011) (Figure 7B). Likewise, anti-RAGE anti-
bodies (1 μg/ml) also reduced the amount of HMGB1-
induced ET-1 release from 381.56 ± 17.3 pg/ml to 348.51 ±
16.3 pg/ml (p = 0.006) (Figure 7C).
Migration and proliferation of vascular smooth muscle
cells are also major pathological features in pulmonary
hypertension vascular lesions. We confirmed the previ-
ously reported proliferative effect of HMGB1 on human
pulmonary artery smooth muscle cells. HPASMCs were
cultured with serum-free medium alone or 10% FBS, or in
the presence of 30 ng/ml HMGB1. Treatment of 30 ng/ml
HMGB1 induced proliferation of HPASMCs compared to
serum-free medium alone (p <0.001) (Figure 7D).
Discussion
In this study, we found that HMGB1 levels in lung tissue
and serum significantly increased in MCT-induced pul-
monary hypertension rats. We also demonstrated that
inhibition of HMGB1 by GLY treatment improved the
survival rates of MCT-induced pulmonary hypertension
rats by reducing pulmonary hypertension and attenuat-
ing pulmonary vascular remodeling and RV hypertrophy.
In addition, in vitro study data supplied in Figure 7 pre-
sents the potential effects of HMGB1 on endothelium
hyperactivity and pulmonary vascular remodeling. These
results suggest that HMGB1 may play a significant role
in the pathophysiology of pulmonary hypertension.
MCT is a toxic pyrrolizidine alkaloid. A single sub-
cutaneous injection of MCT induces severe pulmonaryMCT + GLYMCTmal Control
C
mmation in the MCT-induced pulmonary hypertension rat.
e non-treated MCT group. The survival rate was 60% in the non-treated
= 0.0027). (B, C) The degree of pulmonary inflammation was measured
ed in the MCT group compared with the control group (*p = 0.009).
f the non-treated MCT group (†p = 0.018). Data are presented
A B
C D
Figure 7 HMGB1 induced ET-1 release from HPAECs and proliferation of HPASMCs. (A) HMGB1-stimulated ET-1 release from HPAECs.
Release of ET-1 was approximately 10% higher in the HMGB1-treated (40 ng/ml) group than in the control group (*p <0.001). (B, C) ET-1 release
from HPAECs was attenuated by treatment antibodies against HMGB1 or RAGE in a dose-dependent manner (†p = 0.011; ‡p = 0.006). (D) HPASMCs
were cultured with serum-free medium alone or 10% FBS, or in the presence of 30 ng/ml HMGB1. HMGB1 induced proliferation of HPASMCs
(p <0.001). Data are presented as means ± SEM.
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nisms by which MCT causes pulmonary hypertension
are not fully resolved; however, the proposed mechan-
ism of action is as follows. MCT is activated to the re-
active compound MCT pyrrole in the liver. This MCT
pyrrole causes endothelial injury in the pulmonary
vessels and subsequently induces remodeling of the
precapillary vessels in ways such as medial thickening and
de novo muscularization [27]. In the MCT-injected rats,
the acute inflammatory response is turned off within a
week after MCT injection, and vascular remodeling is ob-
served after 1–2 weeks [23,26]. Our results are consistent
with these data, as serum levels of HMGB1 in pulmonary
hypertension rats were normal in the acute inflammatory
period (comprising the first week after MCT injection),
then increased and remained elevated throughout the vas-
cular remodeling period (2 weeks after MCT injection and
onwards). These findings suggest that the increased levels
of HMGB1 might be more closely related to pulmonary
vascular remodeling of pulmonary arteries than acuteMCT-induced pulmonary vascular inflammation in the
MCT-induced pulmonary hypertension rats.
In our experiments using the MCT-induced pulmonary
hypertension rats, RVSP and RV hypertrophy significantly
decreased in the GLY-treated group compared to the non-
treated group. In addition, GLY treatment significantly
reduced the medial wall thickness of pulmonary arteries
and the muscularization of small pulmonary vessels. These
results indicate that inhibition of HMGB1 by GLY treat-
ment can lead to hemodynamic improvement and attenu-
ation of pulmonary vascular remodeling, at least in the
MCT-induced pulmonary hypertension rats. Furthermore,
GLY treatment also conferred a survival benefit in the
MCT-induced pulmonary hypertension rats. A recent
study from Bauer and co-workers reported that serum
HMGB1 levels were higher in idiopathic pulmonary hyper-
tension patients than in healthy controls, and HMGB1
may contribute to the pathogenesis of experimental pul-
monary hypertension induced by chronic hypoxia [20].
This study shared the same conclusion with that of our
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significant role in the pathophysiology of pulmonary
hypertension; however, used animal model of pulmon-
ary hypertension was different with that of our study.
The MCT-induced pulmonary hypertension rat is one
of the most commonly utilized animal models of pulmon-
ary hypertension, although there are many additional pul-
monary hypertension animal models employing various
chemical, physiological, and molecular interventions. Each
pulmonary hypertension animal model has its own unique
limitations in representing human pulmonary hypertension;
there is no perfect animal model that faithfully reproduces
all pathophysiological features of human pulmonary hyper-
tension [27]. Although our data support a meaningful role
of HMGB1 and demonstrate the therapeutic effects of GLY
in MCT-induced pulmonary hypertension rats, further
investigation into HMGB1 using additional pulmonary
hypertension animal models and clinical studies of patients
diagnosed with pulmonary hypertension are required.
Thus, the study by Bauer and co-workers was helpful in
clarifying our results about the role of HMGB1 in pul-
monary hypertension.
Vasoconstriction promoted by endothelial dysfunction
is one of the major pathologic features of pulmonary
hypertension. ET-1 is a peptide secreted by vascular
endothelial cells that mediates vasoconstriction of pul-
monary arteries and is targeted by one of the classes of
current therapeutics for pulmonary hypertension. In our
in vitro study, ET-1 release by HPAECs was significantly
increased by HMGB1 treatment in a dose-dependent
manner. Moreover, this HMGB1-stimulated increase in
ET-1 release could be inhibited with antibodies against
either HMGB1 or RAGE. These data demonstrate that
HMGB1 can induce ET-1 release from HPAECs via a
RAGE-mediated mechanism. RAGE is a multi-ligand
receptor and is expressed in many types of cells, including
macrophages, neural cells, smooth muscle cells, and endo-
thelial cells. Furthermore, it is well known that HMGB1
can activate endothelial cells by interacting with RAGE,
which ultimately leads to NF-κB activation [18,19,28].
Several studies have also reported that RAGE-dependent
signaling pathways regulate ET-1 release from endothelial
cells. Advanced glycation end product, another ligand of
RAGE, can induce mRNA transcription of ET-1 by
cultured endothelial cells in an NF-κB–dependent manner
[29]. In support of a role for RAGE in this process,
increased ET-1 expression in cultured endothelial cells is
attenuated by RAGE antagonists [30], and serum levels of
ET-1 decrease in RAGE knockout mice [31]. Hypersecre-
tion of ET-1 is an important factor in pulmonary hyper-
tension pathogenesis, and ET-1 antagonism has been
shown to have clinical use in the treatment of pulmonary
hypertension [32]. In addition, the HMGB1-RAGE inter-
action has also been shown to induce migration andproliferation of vascular smooth muscle cells and mesoan-
gioblasts [24,33]. The response of smooth muscle cells to
HMGB1 has been well-characterized in atherosclerotic pla-
ques [16,17]; however, migration and proliferation of vascu-
lar smooth muscle cells are also major pathological features
in pulmonary-hypertension vascular lesions. We con-
firmed the previously reported proliferative effect of
HMGB1 on human pulmonary artery smooth muscle
cells in Figure 7D. Considering its potential effects on
endothelium hyperactivity and pulmonary vascular
remodeling, it is reasonable to envision a valuable role
for HMGB1 in the pathophysiology of pulmonary
hypertension.
Current therapeutic strategies for pulmonary hyper-
tension have mainly focused on vascular hyperactivity.
This approach improves many of the symptoms and
hemodynamic properties of pulmonary hypertension;
however, it has a limited ability to improve vascular
remodeling and patient survival. Inflammatory processes
in pulmonary hypertension are important pathogenic
features for identifying new therapeutic strategies [5-8].
Considering the cytokine activities of HMGB1, it is rea-
sonable to propose that the effects of GLY on MCT-
induced pulmonary hypertension shown in this work are
related to the inflammatory processes of pulmonary
hypertension. In line with this hypothesis, our data showed
that GLY treatment reduced the degree of pulmonary
inflammation, as measured by micro-PET, when compared
with the non-treated MCT group.
We employed GLY, a molecule that binds directly to
HMGB1 and inhibits its cytokine activities, as a chemical
inhibitor of HMGB1 in this study [34,35]. GLY is a nat-
ural compound produced by the licorice plant that has
been used clinically to treat patients with chronic hepa-
titis for more than 30 years, especially in Japan [36,37].
In the previous study, Sitia and co-workers showed that
as an HMGB1 inhibitor, GLY is as effective as Box-A, a
representative HMGB1 direct inhibitor [34]. Our investi-
gation of the therapeutic effects of GLY on pulmonary
hypertension has merit, given that the pharmacological
properties and safety of GLY, two of the most important
hurdles for any new therapy to overcome, are already
well-established.
However, using GLY as an HMGB1 inhibitor also has
several limitations. GLY has various pharmacological
effects [36]; therefore, we cannot jump to the conclu-
sion that the protective effect of GLY is only due to the
inhibition of HMGB1 in spite of previous proof about
its direct binding activity to HMGB1. Another contro-
versial aspect of our study is that it is possible for GLY to
induce an effect that is contradictory to our results. A sin-
gle study from Ruszymah and co-workers showed that
GLY caused an increase in right atrial pressure as well as
thickening of the pulmonary vessels [38]. However, data
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tail blood pressure in GLY-treated rats, and right atrial
pressure was strongly correlated with tail blood pressure.
Pseudoaldosteronism, with sodium retention, hypokal-
emia, and hypertension, is a well-known side-effect of
GLY [36]. Increased RA pressure and thickening of pul-
monary vessels might be indirect results from systemic
hypertension, not from a direct pharmacologic effect of
GLY. Aharinejad and co-workers showed that spontan-
eously hypertensive rats developed pulmonary hyper-
tension and muscularization of pulmonary vessels [39].
It is also worth noting that Ruszymah and co-workers ap-
plied a very high dose (1.0 mg/mL, 40–50 mL/day,
160–200 mg/kg/day for rats with a body weight 250 g) and
a very long term treatment (12 weeks) of GLY compared
with our experiments (50 mg/kg/day, 4 or 6 weeks). We
showed that GLY given alone without MCT in our experi-
mental condition did not lead to any differences in RVSP,
RV hypertrophy, medial wall thickness, or pulmonary
vascular muscularization when compared with normal
control rats.
Due to the above limitations in our study, further studies
with additional HMGB1 inhibitors will be important for
providing additional evidence to support the data pre-
sented here. Two other options for inhibiting HMGB1
involve treatment with either anti-HMGB1 antibodies
or recombinant Box-A, an antagonist that competes
with extracellular HMGB1 [12].
Our animal study protocol is also a limitation due to our
decision to start GLY treatment immediately after MCT
administration. In retrospect, our choice of a preventive
protocol was unwise. Pulmonary hypertension is frequently
misdiagnosed and has often progressed to a late stage by
the time it is accurately diagnosed. A better choice would
be a curative protocol starting GLY treatment at day 7 and
continuing until day 28.Conclusions
In conclusion, we demonstrated that the proinflammatory
cytokine HMGB1 could contribute to the pathophysiology
of pulmonary hypertension. Treatment of pulmonary
hypertension with GLY, an HMGB1 inhibitor, has the
potential to attenuate pulmonary vascular remodeling and
disease progression of pulmonary hypertension. This
approach might constitute a promising novel therapeutic
strategy for human patients with pulmonary hypertension.Abbreviations
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